Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
30 Enero 2024 - 3:15PM
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will
report its fourth quarter and full year 2023 financial results on
Thursday, February 15, 2024 before the U.S. financial markets open.
The company will host a conference call and simultaneous webcast at
8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at
https://www.royaltypharma.com/investors/events/ to obtain
conference call information and to view the live webcast. A replay
of the conference call and webcast will be archived on the
company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie
and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s
Xtandi, GSK’s Trelegy, Novartis’ Promacta, Johnson & Johnson’s
Tremfya, Roche’s Evrysdi, Pfizer’s Nurtec ODT, Gilead’s Trodelvy,
and 12 development-stage product candidates. For more information,
visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6637ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Royalty Pharma (NASDAQ:RPRX)
Gráfica de Acción Histórica
De May 2023 a May 2024